Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M008809200 on October 24, 2000

J. Biol. Chem., Vol. 276, Issue 7, 4634-4639, February 16, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/7/4634    most recent
M008809200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dallongeville, J.
Right arrow Articles by Staels, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dallongeville, J.
Right arrow Articles by Staels, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Peroxisome Proliferator-activated Receptor alpha  Is Not Rate-limiting for the Lipoprotein-lowering Action of Fish Oil*

Jean DallongevilleDagger §, Eric BaugéDagger ||, Anne TailleuxDagger ||**, Jeffrey M. PetersDagger Dagger , Frank J. Gonzalez§§, Jean-Charles FruchartDagger ||**, and Bart StaelsDagger ||**

From the Dagger  Département d'Athérosclérose, § INSERM U-508, and || INSERM U-325, Institut Pasteur de Lille, 59019 Lille, France, ** Faculté de Pharmacie, Université Lille 2, 59000 Lille, France, Dagger Dagger  Center for Molecular Toxicology, the Pennsylvania State University, University Park, Pennsylvania 16802, and the §§ Laboratory of Molecular Carcinogenesis, NCI, National Institutes of Health, Bethesda, Maryland 20892

Received for publication, September 26, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Similar to fibrate hypolipidemic drugs, long chain polyunsaturated fatty acids contained in fish oil are activators of peroxisome proliferator-activated receptor alpha  (PPARalpha ). The goal of this study was to assess the contribution of PPARalpha in mediating the effect of fish oil on plasma lipid, lipoprotein, and apolipoprotein levels. To this end, PPARalpha -deficient mice and wild-type littermates were fed isocaloric fish oil or coconut oil diets, the content of which varied reciprocally between 0, 3, 7, and 10% for 1 week. In both wild-type and PPARalpha -deficient mice, fish oil feeding was associated with a dose-dependent decrease in triglycerides, cholesterol, and phospholipids associated with lower levels of very low density lipoprotein (VLDL) triglycerides and high density lipoprotein (HDL) cholesterol. The lowering of triglycerides and VLDL triglycerides was associated with a significant decrease of plasma apoC-III in both genotypes. Fish oil treatment did not influence hepatic apoC-III mRNA levels in either genotype indicating that apoC-III is not under transcriptional control by fish oil. The lowering of HDL cholesterol observed in both genotypes was associated with reduced plasma apoA-II without changes in liver apoA-II mRNA levels. In contrast, plasma apoA-I and liver apoA-I mRNA levels were decreased in wild-type but not in PPARalpha -deficient mice after fish oil feeding indicating that PPARalpha contributes to the effect of fish oil on apoA-I gene expression. In conclusion, PPARalpha is not rate-limiting for fish oil to exert its triglyceride- and HDL-lowering action. Furthermore, PPARalpha mediates, at least partly, the decrease of apoA-I after fish oil treatment, whereas apoC-III and apoA-II levels are affected in a PPARalpha -independent manner. Altogether, these results show major molecular differences in action between fibrates and fish oil providing a molecular rationale for combination treatment with these compounds.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Fish oil treatment efficiently lowers lipids in patients with hypertriglyceridemia (1, 2). In addition to its effect on triglyceride-rich lipoproteins, fish oil decreases HDL1 levels in rodents and to a lesser extent in humans (2, 3). Fish oil acts by modulating the activity of several enzymes of lipid and carbohydrate metabolism, such as diacylglycerol acyltransferase, fatty-acid synthase, carnitine palmitoyltransferase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, acetyl-CoA carboxylase and Delta 9-desaturase (4). Fish oil and its major long chain fatty acids, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acid, appear to affect most hepatic enzyme activities by regulating the expression of their genes (4). The resultant effect is a decrease in triglyceride synthesis (5) and an increase in fatty acid mitochondrial beta -oxidation (6-8). This, in turn, results in decreased formation and production of VLDL (9).

High fat diets also increase peroxisome proliferation in liver, kidney, and heart of rodents (10). Coincident with an increase in the number of peroxisomes, peroxisomal enzymes are induced by transcriptional activation. Several of these enzymes are controlled by the peroxisome proliferator-activated receptor alpha  (PPARalpha ) (11-13). PPARalpha belongs to the superfamily of nuclear receptors that function as ligand-activated transcription factors. In addition to PPARalpha , the PPAR family comprises PPARgamma and PPARdelta . PPARs heterodimerize with the retinoid X receptor and alter transcription of target genes after binding to peroxisome proliferator response elements. In vitro PPAR is activated by fatty acids that bind to a ligand binding domain in its C-terminal region (14-20). In addition, compounds such as fibrates, certain prostaglandins and leukotrienes, and oxidized fatty acid derivates also bind to and activate PPARs. These observations suggest that fish oil may exert its metabolic and lipid-lowering properties by activating PPARs. In agreement with this hypothesis, studies in PPARalpha -deficient mice have demonstrated that PPARalpha is necessary for fish oil to activate gene expression of enzymes of fatty acid oxidation such as acyl-CoA oxidase and cytochrome P450-4A2 but is not necessary to inhibit gene expression of fatty-acid synthase and S14 protein (21, 22).

To date, the exact contribution of the PPARalpha pathway to the lipid- and lipoprotein-lowering properties of fish oil has not been defined. Moreover, its contribution to the changes in circulating apolipoprotein levels after fish oil treatment has not been described. Therefore, the goal of the present study was to assess the role of the PPARalpha pathway in mediating the fish oil-dependent lipid, lipoprotein and apolipoprotein alterations. To this end, the effects of increasing consumption of fish oil on lipid and apolipoprotein levels were assessed in wild-type and PPARalpha -deficient mice. The results of the present study indicate that PPARalpha has a minor role in the fish oil-induced lowering of triglyceride and HDL cholesterol levels in mice. In this respect, fish oil acts differently than synthetic PPARalpha activators such as fibrates.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Animals-- The studies were performed with wild-type and PPARalpha -deficient mice (23) in the SV129 genetic background. Before dietary experiments all animals were acclimatized for more than 2 weeks under conditions of controlled temperature (20 ± 1 °C) and lighting (dark from 8 p.m. to 8 a.m.) in a room of low background noise. The average age of the mice was 8 weeks.

Experiments-- For all experiments, male wild-type and PPARalpha -deficient mice were used. Before each dietary experiment a blood sample was drawn for randomization on triglyceride levels. Animals were housed in cages (2-3 per cage) and given free access to a fat-free semi-purified diet (UAR, Villemoisson sur Orge, France) supplemented with coconut oil, fish oil, or fenofibrate (Sigma). Fish oil and coconut oil were obtained from menhaden and copra, respectively, and were purchased from Sigma. Fish oil contained 30% of n - 3 fatty acid, and the EPA to DHA ratio was 1.2. Duration of experimental dietary exposure was 1 week in all experiments. For experiment 1, three groups of 6 SV129 mice were supplemented with an isocaloric diet containing either 10% (w/w) coconut oil alone, 10% (w/w) coconut plus 0.2% (w/w) fenofibrate, or 10% (w/w) fish oil alone. For experiment 2, wild-type or PPARalpha -deficient mice were fed an isocaloric diet supplemented with either 10% (w/w) coconut oil alone, 7% coconut oil plus 3% fish oil, 3% coconut oil plus 7% fish oil, or 10% fish oil alone. The other major nutrient components were carbohydrate (50.4 g/100 g), casein (18 g/100 g), cellulose (4.8 g/100 g), salt mixture (5.6 g/100 g), and vitamins (0.8 g/100 g). At the end of each dietary experiment, mice were food-deprived for 4 h and were exsanguinated under diethyl ether anesthesia by cardiac puncture. Blood samples were collected on EDTA tubes.

Lipoprotein Separation and Measurements-- Plasma was separated by centrifugation (630 × g) for 20 min at 4 °C. Lipids were determined enzymatically using commercially available kits for triglycerides (Triglycerides GPO-PAP, Roche Molecular Biochemicals), cholesterol (Cholesterol C System, Roche Molecular Biochemicals), and phospholipids (Phospholipids PAP 150, BioMérieux, Lyon, France). Plasma levels of mouse apoA-I, apoA-II, and apoC-III were measured by immunonephelemetric assays using specific polyclonal antibodies in a fixed time method in a Behring Nephelometric Analyzer (Behring Diagnostics, Marburg, Germany). For these assays, the primary standard was a pool of sera from normolipidemic C57BL/6 mice to which an arbitrary concentration of 100, 50, and 20 mg/dl was attributed for apoA-I, apoA-II, and apoC-III, respectively. With this standard, the calibration curves cover the ranges 1.25-40 mg/dl for apoA-I, 0.62-20 mg/dl for apoA-II, and 0.123-4 mg/dl for apoC-III. As the exact concentration of apolipoproteins of the standard is unknown, it was more convenient to express the results of the experimental groups as percentage of the control group. Accordingly, the correlations between apoA-I and HDL were r = 0.96 and between apoC-III and triglycerides were r = 0.80 in 20 serum samples. The variation coefficients were below 6% for the 3 parameters including within and between-day variation. Antibodies were raised in rabbit by immunization with synthetic peptides reproducing a part of murine apoA-I sequence, the complete apoA-II sequence, and with native murine apoC-III prepared by isoelectrofocusing.

Gel Filtration Chromatography (FPLC)-- Gel filtration chromatography was performed using a Superose 6 HR 10/30 column (Amersham Pharmacia Biotech) from 100 µl of plasma. The gel was allowed to equilibrate with phosphate-buffered saline (10 mM) containing 0.01% EDTA and 0.01% sodium azide; 200 µl of plasma were eluted with the buffer at room temperature at a flow rate of 0.2 ml min-1. Elution profiles were monitored at 280 nm and recorded with an analog recorder chart tracing system (Amersham Pharmacia Biotech). The effluents were collected in 0.22-ml fractions. Triglycerides, cholesterol, and phospholipids were measured in each collected fraction using commercially available enzymatic kits (Triglycerides GPO-PAP or Cholesterol C System, Roche Molecular Biochemicals and Phospholipid Enzymatic PAP 150, BioMérieux, Lyon, France).

RNA Analysis-- Total cellular RNA was isolated from liver tissue by the acid guanidinium thiocyanate/phenol chloroform method (24). Northern and dot-blot hybridizations were performed exactly as described previously (25). The rat apoA-I, apoA-II, apoC-III, acyl-CoA oxidase, CYP450, and human acidic ribosomal phosphoprotein 36B4 cDNA (25-27) were used as probes. All probes were labeled by random primed labeling (Roche Molecular Biochemicals). Filters were hybridized to 1 × 106 cpm·ml-1 of each probe as described (28). They were washed in 300 ml of 75 mM NaCl, 7.5 mM sodium citrate, pH 7.4, and 0.1% SDS for 10 min at room temperature and twice for 30 min at 65 °C and subsequently exposed to x-ray film (Kodak X-Omat-AR, Eastman Kodak Co.). Autoradiograms were analyzed by quantitative scanning densitometry (Bio-Rad GS670 Densitometer, Bio-Rad) in the linear range of film sensitivity. Curves were plotted on a log/log scale relating the density measurements to the amounts of mRNA in the corresponding dots. The relative amounts of mRNA were calculated using the parallel, linear parts of these curves as described elsewhere (28, 29).

Statistical Analysis-- Student's t test was used to compare treatment effects within each genotype. The SPSS Software release 7.5 for Windows was used (SPSS Institute Inc., Paris, France).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Effect of Fenofibrate and Fish Oil on Lipid Levels in SV129 Mice Strain-- To test whether mice of the SV129 strain respond to PPARalpha activators, we tested the effect of fenofibrate (0.2% w/w) and fish oil (10% w/w) on lipid metabolism in this mice strain. Plasma triglycerides, cholesterol, and phospholipids were lower in SV129 mice supplemented with fish oil than in those on the coconut oil diet (Table I). These effects were accounted for by lower levels of both the large triglyceride-rich and the small cholesterol-rich lipoprotein fraction as assessed by gel filtration chromatography (data not shown). In contrast, fenofibrate decreased triglyceride levels but not cholesterol and phospholipid concentrations in the SV129 mice.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Plasma lipid levels in SV129 mice treated with fenofibrate or fish oil
SV129 mice were treated for 1 week with 10% (w/w) coconut oil alone, 10% (w/w) coconut oil plus 0.2% (w/w) fenofibrate, and 10% (w/w) fish oil alone. Lipids were analyzed as indicated under "Materials and Methods." Values are means ± S.D. of six animals per group.

Effect of Fenofibrate and Fish Oil on Liver Acyl-CoA Oxidase, ApoA-I, ApoA-II, and ApoC-III mRNA Levels in SV129 Mice Strain-- To test whether mice of the SV129 strain respond to PPARalpha activators by peroxisomal proliferation and apolipoprotein gene expression changes, the effect of fenofibrate (0.2% w/w) and fish oil (10% w/w) on liver acyl-CoA oxidase, apoC-III, apoA-I, and apoA-II mRNA levels were analyzed (Fig. 1). Liver acyl-CoA oxidase mRNA levels were higher in SV129 mice treated with fenofibrate (approximately ×10) than in those supplemented with coconut oil. In contrast, liver acyl-CoA oxidase mRNA levels was mildly induced (approximately ×1.4) by fish oil feeding. Liver apoC-III and apoA-I mRNA levels were lower in the fenofibrate group than in the coconut oil group, whereas apoA-I, but not apoC-III, was decreased by fish oil feeding in this mice strain. Finally, liver apoA-II mRNA levels were markedly increased by fenofibrate feeding but not affected by fish oil treatment.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 1.   Liver acyl-CoA oxidase, apoC-III, apoA-I, and apoA-II mRNA levels in SV129 mice fed 10% (w/w) coconut oil alone (CO), 10% (w/w) coconut oil plus 0.2% (w/w) fenofibrate (FENO), and 10% (w/w) fish oil alone (FO) for 1 week. Each value represents mean of 6 mice per group. p values are for t test comparison with coconut oil group: ***, p < 0.0001; **, p < 0.001; *, p < 0.05.

Dose-dependent Effects of Fish Oil on Lipid and Lipoprotein Levels in Wild-type and PPARalpha -deficient Mice-- To assess whether PPARalpha mediates the effect of fish oil on plasma lipids, a dose-response study was performed in wild-type and PPARalpha -deficient mice (Table II). Plasma cholesterol, triglycerides, and phospholipids were lower in both wild-type and PPARalpha -deficient mice fed fish oil than in those fed coconut oil (Table II). The lowering effect of fish oil on cholesterol, triglyceride, and phospholipid levels was already discerned at 3% (w/w) supplementation in both genotypes. The decrease in cholesterol, triglyceride, and phospholipid levels was dose-dependent and of similar amplitude in wild-type and PPARalpha -deficient mice. Triglyceride levels were lower in the large FPLC plasma lipid fraction, corresponding to VLDL, of both wild-type and PPARalpha -deficient mice supplemented with increasing doses of fish oil (Fig. 2). Cholesterol and phospholipid peaks were lower in the small FPLC plasma lipid fraction, corresponding to HDL, of wild-type and PPARalpha -deficient mice fed fish oil than in those fed coconut oil. Therefore, the decreases in plasma triglyceride and cholesterol levels were accounted for by a lowering of VLDL and HDL, respectively, in both genotypes.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Plasma lipid levels in wild-type and PPARalpha -deficient mice fed an isocaloric diet containing increasing amounts of fish oil
Wild-type and PPARalpha -deficient mice were fed the following diets for 1 week: fish oil 0% contained 10% (w/w) coconut oil; 3%, 3% (w/w) fish oil plus 7% (w/w) coconut oil; 7%, 7% (w/w) fish oil plus 3% (w/w) coconut oil; 10%, 10% (w/w) fish oil. Values are means ± S.D. of six animals per group.



View larger version (26K):
[in this window]
[in a new window]
  		Fig. 2.   Plasma triglyceride and cholesterol distribution of wild-type and PPARalpha -deficient mice fed increasing proportions of fish oil (FO) (see Table II for diet composition). Plasma lipoproteins were separated by gel filtration chromatography (FPLC) using a Superose 6HR 10/30 column. Cholesterol and triglycerides were measured in eluted fractions using enzymatic methods. Values are pools of six mice per treatment group.

Effect of Fish Oil on Liver Acyl-CoA Oxidase and CYP450 mRNA Levels-- To assess whether fish oil and PPARalpha deficiency affect peroxisomal proliferation, liver acyl-CoA oxidase and CYP450 mRNA levels were measured (Fig. 3). Liver acyl-CoA oxidase mRNA levels were induced by ~1.4-fold and in liver CYP450 mRNA levels by 3-fold in wild-type but not in PPARalpha -deficient mice.



View larger version (13K):
[in this window]
[in a new window]
  		Fig. 3.   Liver CYP450 mRNA levels of wild-type and PPARalpha -deficient mice fed 10% coconut oil (open bar) or 10% fish oil (dark bar) for 1 week. Values are means of 11 mice per group. p values are for t test comparison with coconut oil group: ***, p < 0.0001; **, p < 0.001; *, p < 0.05.

Effect of Fish Oil on Plasma ApoC-III and Liver ApoC-III mRNA Levels-- The effect of fish oil on circulating apolipoprotein C-III levels in wild-type and PPARalpha -deficient mice was assessed (Fig. 4). Plasma apoC-III levels were lower in both PPARalpha -deficient and in wild-type mice fed fish oil than in those fed with coconut oil. There was no evidence for a statistically significant effect of fish oil on liver apoC-III mRNA levels in either genotype.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 4.   Plasma apoC-III and liver apoC-III mRNA levels of wild-type and PPARalpha -deficient mice fed 10% coconut oil (open bar) or 10% fish oil (dark bar) for 1 week. Values are means of 11 mice per group. p values are for t test comparison with coconut oil group: ***, p < 0.0001; **, p < 0.001; *, p < 0.05.

Effect of Fish Oil on Plasma and Liver mRNA Levels of Apolipoprotein A-I and A-II-- Next, we examined the effect of fish oil on the major HDL apolipoproteins (Fig. 5). Fish oil supplementation was associated with a decrease in plasma apoA-I levels in both mice strains. This decrease was less pronounced in the PPARalpha -deficient mice. Similarly, liver apoA-I mRNA levels were lower after fish oil feeding in wild-type but not in PPARalpha -deficient mice suggesting that PPARalpha contributes to the fish oil-mediated lowering of plasma apoA-I and liver apoA-I mRNA levels. Plasma apoA-II levels were lower in both PPARalpha -deficient and in wild-type mice fed with fish oil than in those fed with coconut oil (Fig. 6). However, fish oil had mild liver apoA-II mRNA levels raising effect in both wild-type and PPARalpha -deficient mice.



View larger version (13K):
[in this window]
[in a new window]
  		Fig. 5.   Plasma apoA-I and liver apoA-I mRNA levels of wild-type and PPARalpha -deficient mice fed 10% coconut oil (open bar) or 10% fish oil (dark bar) for 1 week. Values are means of 11 mice per group. p values are for t test comparison with coconut oil group: ***, p < 0.0001; **, p < 0.001; *, p < 0.05.



View larger version (14K):
[in this window]
[in a new window]
  		Fig. 6.   Plasma apoA-II (upper panel) and liver apoA-II mRNA levels (lower panel) of wild-type and PPARalpha -deficient mice fed 10% coconut oil (open bar) or 10% fish oil (dark bar) for 1 week. Values are means of 11 mice per group. p values are for t test comparison with coconut oil group: ***, p < 0.0001; **, p < 0.001; *, p < 0.05.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The results of the present study show that fish oil has similar effects on cholesterol, triglyceride, and HDL cholesterol levels in wild-type and PPARalpha -deficient mice suggesting that PPARalpha is not rate-limiting for fish oil to lower plasma lipid and lipoprotein levels. This finding is different to what is observed with fibrates (32) and suggests that fibrates and fish oil affect lipoprotein metabolism through different mechanisms of action. The lowering of plasma triglyceride was associated with decreased levels of apoC-III in both wild-type and PPARalpha . Like fibrates, fish oil lowered apoA-I and liver apoA-I mRNA level in wild-type but not in PPARalpha -deficient mice suggesting a contribution of PPARalpha . These results indicate that, in contrast to fibrates, fish oil has different molecular mechanisms of action on triglyceride and HDL metabolism.

In contrast to fibrates, fish oil decreased triglyceride levels to a similar extent in wild-type and PPARalpha -deficient mice suggesting that fish oil exerts its triglyceride-lowering properties through mechanisms that are independent of PPARalpha . There are a number of possible hypotheses to explain these differences between fish oil and fibrates. First, although long chain fatty acids, including EPA and DHA, bind and activate PPARalpha (14), the affinity and the ability of these fatty acids to activate PPARalpha is much smaller than that of pharmacological activators such as fibrates (15-20). For example the effect of fish oil on acyl-CoA oxidase expression is much lower than that of fibrates suggesting that the contribution of fatty acid oxidation to the triglyceride-lowering activity of fish oil treatment is minor in mice. In fact, fish oil fatty acids might not be potent enough to activate PPARalpha to a level where it exerts a significant metabolic effect in vivo. However, in our experiments fish oil treatment regulated apoA-I, acyl-CoA oxidase, and CYP450 gene expression in a PPARalpha -dependent manner indicating that this hypothesis is unlikely to be true. Second, fish oil may regulate the same genes controlling triglyceride metabolism as fibrates through mechanisms of actions independent of PPARalpha . For example, the activity of a number of lipogenic enzymes such as the S14 protein and fatty-acid synthase which are conspicuously decreased by fish oil treatment (33, 34) are under the control of the SREBP1 transcription factor (35, 36). Recent studies have shown that SREBP1 expression is decreased by long chain polyunsaturated fatty acids (36-39). Third, in contrast to fibrates EPA and DHA activate PPARgamma , which induces lipoprotein lipase in a tissue-specific manner in adipose tissue, it is likely that a part of the triglyceride-lowering activity of fish oil treatment occurs through activation of this nuclear receptor in adipose tissue. Finally, PPARalpha agonists and fish oil may affect different subsets of genes, by currently unknown mechanisms, that are important for triglyceride metabolism.

ApoC-III plays a crucial role in triglyceride metabolism. Earlier studies have demonstrated that apoC-III inhibits VLDL lipolysis and uptake by cellular receptors (40-42) and that overexpression of apoC-III in mice is associated with elevated levels of triglycerides due to a defective clearance of VLDL (43). Fibrate treatment has been shown to decrease hepatic apoC-III mRNA and plasma apoC-III levels, an effect contributing to the triglyceride-lowering activity of these drugs. Interestingly, although plasma apoC-III concentrations are also reduced by ~80% by fish oil, this diet did not decrease hepatic apoC-III mRNA levels, an observation that is in sharp contrast to fibrates (32). These observations further point out a difference between fibrates and fish oil. Thus, the major reduction of plasma apoC-III levels (-80%) as compared with the lack of effect of fish oil on liver apoC-III mRNA suggests that nontranscriptional mechanisms contribute to the lowering of plasma apoC-III after fish oil treatment.

Previous studies have shown that replacing saturated by polyunsaturated fatty acids results in the lowering of HDL cholesterol in rodents as well as in humans (44-46). The mechanism of this effect is not clear since either decreased production rates or increased catabolic rates of apoA-I were described depending on the experimental models, the type of diets, and the metabolic parameters that were measured (47-50). Moreover, hepatic apoA-I mRNA levels were either lowered or not affected by the substitution of saturated by polyunsaturated fatty acids in the diet (44, 48-53). In this study, fish oil supplementation resulted in lower levels of HDL cholesterol and HDL phospholipids in both genotypes, indicating a PPARalpha -independent lowering action of fish oil on HDL lipids. In contrast with this finding, plasma apoA-I and liver apoA-I mRNA levels were decreased in wild-type mice, but not in the PPARalpha -deficient mice, after fish oil feeding. These observations indicate that PPARalpha contributes to the effect of fish oil on apoA-I expression. Previous studies in our laboratory have shown that fibrates decrease apoA-I gene transcription in rodents (25, 32, 54). This effect was shown to be due to the activation of PPARalpha (32, 55). In the present study, the observation that fish oil requires PPARalpha to exert part of its apoA-I-lowering effect suggests that fish oil and fibrates share, at least in part, a common molecular pathway of apoA-I regulation. Furthermore, the dissociation between the effect of fish oil on HDL lipids and apoA-I suggests that other or additional proteins other than apoA-I regulate HDL lipids levels and that these proteins are not under a major PPARalpha control. In this respect, apolipoprotein A-II is another major protein of HDL (56) whose expression is transcriptionally induced by activation of PPARalpha in mice and humans (25, 32, 57). However, in contrast to fibrate treatment, apoA-II levels were lowered by fish oil feeding as well in wild-type and PPARalpha -deficient mice. Furthermore and in contrast to apoA-I, liver apoA-II mRNA levels were not affected by fish oil treatment. The observed changes in plasma apoA-II concentrations might be due to a (post) translational repression of its production or secondary to intravascular metabolic changes. Although further studies are required to elucidate the molecular mechanisms involved therein, our results clearly demonstrate a distinct regulation of apoA-II by fibrates and fish oil.

In conclusion, the results of the present study indicate that fish oil decreases triglyceride and HDL levels to a similar extend in wild-type and PPARalpha -deficient mice suggesting that PPARalpha is not rate-limiting for fish oil to exert its lipid- and lipoprotein-lowering action. The decrease in triglyceride levels was associated with a decrease in plasma apoC-III which occurs independently of PPARalpha . The lowering of HDL cholesterol was accompanied by a decrease in plasma apoA-I, apoA-II, and liver apoA-I mRNA. The effect on plasma apoA-I and liver apoA-I mRNA levels was abolished by PPARalpha deficiency indicating a contribution of PPARalpha to this effect. Altogether, these data suggest that although fibrates and fish oil have a very similar lipid- and apolipoprotein-lowering profile, they exert their lipid-lowering action through different molecular mechanisms of action.


    ACKNOWLEDGEMENTS

We thank Bruno Derudas and Jacques Frémaux for technical assistance.


    FOOTNOTES

* This study was supported by INSERM and the Pasteur Institute of Lille.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dépt. d'Athérosclérose, Institut Pasteur de Lille, 1 Rue du Professeur Calmette, 59019 Lille Cedex, France. Tel.: 33 320 877 373; Fax: 33 320 877 360; E-mail: jean.dallongeville@pasteur-lille.fr.

Published, JBC Papers in Press, October 24, 2000, DOI 10.1074/jbc.M008809200


    ABBREVIATIONS

The abbreviations used are: HDL, high density lipoprotein; VLDL, very low density lipoprotein; PPARalpha , peroxisome proliferator-activated receptor alpha ; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; FPLC, fast protein liquid chromatography; PIPES, 1,4-piperazinediethanesulfonic acid.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Harris, W. S. (1989) J. Lipid Res. 30, 785-807
2. Harris, W. S. (1997) Am. J. Clin. Nutr. 65, 1645-1654
3. Harris, W. S. (1997) Am. J. Clin. Nutr. 65, 1611-1616
4. Jump, D. B., and Clarke, S. D. (1999) Annu. Rev. Nutr. 19, 63-90., 63-90
5. Wong, S., Reardon, M., and Nestel, P. (1985) Metabolism 34, 900-905
6. Willumsen, N., Skorve, J., Hexeberg, S., Rustan, A. C., and Berge, R. K. (1993) Lipids 28, 683-690
7. Halminski, M. A., Marsh, J. B., and Harrison, E. H. (1991) J. Nutr. 121, 1554-1561
8. Gronn, M., Christensen, E., Hagve, T. A., and Christophersen, B. O. (1992) Biochim. Biophys. Acta 1125, 35-43
9. Nossen, J. O., Rustan, A. C., Gloppestad, S. H., Malbakken, S., and Drevon, C. A. (1986) Biochim. Biophys. Acta 879, 56-65
10. De Craemer, D., Vamecq, J., Roels, F., Vallee, L., Pauwels, M., and Van den Branden, C. (1994) J. Lipid Res. 35, 1241-1250
11. Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., and Fruchart, J. C. (1998) Circulation 98, 2088-2093
12. Schoonjans, K., Martin, G., Staels, B., and Auwerx, J. (1997) Curr. Opin. Lipidol. 8, 159-166
13. Schoonjans, K., Staels, B., and Auwerx, J. (1996) J. Lipid Res. 37, 907-925
14. Issemann, I., and Green, S. (1990) Nature 347, 645-650
15. Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., Kliewer, S. A., and Milburn, M. V. (1999) Mol. Cell 3, 397-403
16. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. (1992) Cell 68, 879-887
17. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2160-2164
18. Bocos, C., Gottlicher, M., Gearing, K., Banner, C., Enmark, E., Teboul, M., Crickmore, A., and Gustafsson, J. A. (1995) J. Steroid Biochem. Mol. Biol. 53, 467-473
19. Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., and Wahli, W. (1997) Mol. Endocrinol. 11, 779-791
20. Forman, B. M., Chen, J., and Evans, R. M. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4312-4317
21. Ren, B., Thelen, A. P., Peters, J. M., Gonzalez, F. J., and Jump, D. B. (1997) J. Biol. Chem. 272, 26827-26832
22. Ren, B., Thelen, A., and Jump, D. B. (1996) J. Biol. Chem. 271, 17167-17173
23. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995) Mol. Cell. Biol. 15, 3012-3022
24. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159
25. Berthou, L., Saladin, R., Yaqoob, P., Branellec, D., Calder, P., Fruchart, J. C., Denefle, P., Auwerx, J., and Staels, B. (1995) Eur. J. Biochem. 232, 179-187
26. Staels, B., Van Tol, A., Andreu, T., and Auwerx, J. (1992) Arterioscler. Thromb. 12, 286-294
27. Andersson, Y., Majd, Z., Lefebvre, A. M., Martin, G., Sechkin, A. V., Kosykh, V., Fruchart, J. C., Najib, J., and Staels, B. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 115-121
28. Staels, B., Auwerx, J., Chan, L., Van Tol, A., Rosseneu, M., and Verhoeven, G. (1989) J. Lipid Res. 30, 1137-1145
29. Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., and Auwerx, J. (1995) J. Clin. Invest. 95, 705-712
30. Ramirez, I., Kryski, A. J., Ben-Zeev, O., Schotz, M. C., and Severson, D. L. (1985) Biochem. J. 232, 229-236
31. Burgaya, F., Peinado, J., Vilaro, S., Llobera, M., and Ramirez, I. (1989) Biochem. J. 259, 159-166
32. Peters, J. M., Hennuyer, N., Staels, B., Fruchart, J. C., Fievet, C., Gonzalez, F. J., and Auwerx, J. (1997) J. Biol. Chem. 272, 27307-27312
33. Rustan, A. C., Nossen, J. O., Christiansen, E. N., and Drevon, C. A. (1988) J. Lipid Res. 29, 1417-1426
34. Power, G. W., and Newsholme, E. A. (1997) J. Nutr. 127, 2142-2150
35. Xu, J., Nakamura, M. T., Cho, H. P., and Clarke, S. D. (1999) J. Biol. Chem. 274, 23577-23583
36. Mater, M. K., Thelen, A. P., Pan, D. A., and Jump, D. B. (1999) J. Biol. Chem. 274, 32725-32732
37. Pai, J. T., Guryev, O., Brown, M. S., and Goldstein, J. L. (1998) J. Biol. Chem. 273, 26138-26148
38. Worgall, T. S., Sturley, S. L., Seo, T., Osborne, T. F., and Deckelbaum, R. J. (1998) J. Biol. Chem. 273, 25537-25540
39. Kim, H. J., Takahashi, M., and Ezaki, O. (1999) J. Biol. Chem. 274, 25892-25898
40. Windler, E., Chao, Y., and Havel, R. J. (1980) J. Biol. Chem. 255, 8303-8307
41. Wang, C. S., McConathy, W. J., Kloer, H. U., and Alaupovic, P. (1985) J. Clin. Invest. 75, 384-390
42. Quarfordt, S. H., Michalopoulos, G., and Schirmer, B. (1982) J. Biol. Chem. 257, 14642-14647
43. Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., and Breslow, J. L. (1990) Science 249, 790-793
44. Brousseau, M. E., Ordovas, J. M., Osada, J., Fasulo, J., Robins, S. J., Nicolosi, R. J., and Schaefer, E. J. (1995) J. Nutr. 125, 425-436
45. Leach, A. B., and Holub, B. J. (1984) Lipids 19, 25-33
46. Grundy, S. M., and Denke, M. A. (1990) J. Lipid Res. 31, 1149-1172
47. Shepherd, J., Packard, C. J., Patsch, J. R., Gotto, A. M. J., and Taunton, O. D. (1978) J. Clin. Invest. 61, 1582-1592
48. Sorci-Thomas, M., Prack, M. M., Dashti, N., Johnson, F., Rudel, L. L., and Williams, D. L. (1989) J. Lipid Res. 30, 1397-1403
49. Stucchi, A. F., Hennessy, L. K., Vespa, D. B., Weiner, E. J., Osada, J., Ordovas, J. M., Schaefer, E. J., and Nicolosi, R. J. (1991) Arterioscler. Thromb. 11, 1719-1729
50. Brousseau, M. E., Schaefer, E. J., Stucchi, A. F., Osada, J., Vespa, D. B., Ordovas, J. M., and Nicolosi, R. J. (1995) Atherosclerosis 115, 107-119
51. Kushwaha, R. S., McMahan, C. A., Mott, G. E., Carey, K. D., Reardon, C. A., Getz, G. S., and McGill, H. C. J. (1991) J. Lipid Res. 32, 1929-1940
52. Sorci-Thomas, M., Hendricks, C. L., and Kearns, M. W. (1992) J. Lipid Res. 33, 1147-1156
53. Ahn, Y. S., Smith, D., Osada, J., Li, Z., Schaefer, E. J., and Ordovas, J. M. (1994) J. Nutr. 124, 2147-2155
54. Berthou, L., Duverger, N., Emmanuel, F., Langouet, S., Auwerx, J., Guillouzo, A., Fruchart, J. C., Rubin, E., Denefle, P., Staels, B., and Branellec, D. (1996) J. Clin. Invest. 97, 2408-2416
55. Vu-Dac, N., Chopin-Delannoy, S., Gervois, P., Bonnelye, E., Martin, G., Fruchart, J. C., Laudet, V., and Staels, B. (1998) J. Biol. Chem. 273, 25713-25720
56. Mahley, R. W., Innerarity, T. L., Rall, S. C. J., and Weisgraber, K. H. (1984) J. Lipid Res. 25, 1277-1294
57. Vu-Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J. C., Staels, B., and Auwerx, J. (1995) J. Clin. Invest. 96, 741-750

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Vanschoonbeek, K. Wouters, P. E.J. van der Meijden, P. J. van Gorp, M. A.H. Feijge, M. Herfs, L. J. Schurgers, M. H. Hofker, M. P.M. de Maat, and J. W.M. Heemskerk
Anticoagulant Effect of Dietary Fish Oil in Hyperlipidemia: A Study of Hepatic Gene Expression in APOE2 Knock-in Mice
Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 2023 - 2029.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
D. C Chan, G. F Watts, M. N Nguyen, and P H. R Barrett
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity
Am. J. Clinical Nutrition, July 1, 2006; 84(1): 37 - 43.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
I. J. A. M. Jonkers, A. H. M. Smelt, H. M. G. Princen, F. Kuipers, J. A. Romijn, R. Boverhof, A. A. M. Masclee, and F. Stellaard
Fish Oil Increases Bile Acid Synthesis in Male Patients with Hypertriglyceridemia
J. Nutr., April 1, 2006; 136(4): 987 - 991.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
Y. Li, T. Y. Nara, and M. T. Nakamura
Peroxisome proliferator-activated receptor {alpha} is required for feedback regulation of highly unsaturated fatty acid synthesis
J. Lipid Res., November 1, 2005; 46(11): 2432 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
A. S. Wright-Rodgers, M. K. Waldron, K. E. Bigley, G. E. Lees, and J. E. Bauer
Dietary Fatty Acids Alter Plasma Lipids and Lipoprotein Distributions in Dogs during Gestation, Lactation, and the Perinatal Period
J. Nutr., September 1, 2005; 135(9): 2230 - 2235.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
O. Olivieri, N. Martinelli, M. Sandri, A. Bassi, P. Guarini, E. Trabetti, F. Pizzolo, D. Girelli, S. Friso, P. F. Pignatti, et al.
Apolipoprotein C-III, n-3 Polyunsaturated Fatty Acids, and "Insulin-Resistant" T-455C APOC3 Gene Polymorphism in Heart Disease Patients: Example of Gene-Diet Interaction
Clin. Chem., February 1, 2005; 51(2): 360 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. J. Davidoff, M. M. Mason, M. B. Davidson, M. W. Carmody, K. K. Hintz, L. E. Wold, D. A. Podolin, and J. Ren
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments
Am J Physiol Endocrinol Metab, May 1, 2004; 286(5): E718 - E724.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Sethi, O. Ziouzenkova, H. Ni, D. D. Wagner, J. Plutzky, and T. N. Mayadas
Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPARalpha
Blood, July 30, 2002; 100(4): 1340 - 1346.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
C. Vasandani, A. I. Kafrouni, A. Caronna, Y. Bashmakov, M. Gotthardt, J. D. Horton, and D. K. Spady
Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice
J. Lipid Res., May 1, 2002; 43(5): 772 - 784.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. B. Jump
The Biochemistry of n-3 Polyunsaturated Fatty Acids
J. Biol. Chem., March 8, 2002; 277(11): 8755 - 8758.
[Full Text] [PDF]

Home page
 J. Nutr.Home page
P.-M. Chao, C.-Y. Chao, F.-J. Lin, and C.-j. Huang
Oxidized Frying Oil Up-Regulates Hepatic Acyl-CoA Oxidase and Cytochrome P450 4 A1 Genes in Rats and Activates PPAR{alpha}
J. Nutr., December 1, 2001; 131(12): 3166 - 3174.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/7/4634    most recent
M008809200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dallongeville, J.
Right arrow Articles by Staels, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dallongeville, J.
Right arrow Articles by Staels, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement